ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling – a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial

ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling – a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial

Abstract Background An increasing number of trials indicate that treatment outcomes in cancer patients with metastatic disease are improved when targeted treatments are matched with druggable genomic alterations in individual patients (pts). An estimated 30–80% of advanced solid tumors harbor action...

Full description

Bibliographic Details
Main Authors: Tina Kringelbach, Martin Højgaard, Kristoffer Rohrberg, Iben Spanggaard, Britt Elmedal Laursen, Morten Ladekarl, Charlotte Aaquist Haslund, Laurine Harsløf, Laila Belcaid, Julie Gehl, Lise Søndergaard, Rikke Løvendahl Eefsen, Karin Holmskov Hansen, Annette Raskov Kodahl, Lars Henrik Jensen, Marianne Ingerslev Holt, Trine Heide Oellegaard, Christina Westmose Yde, Lise Barlebo Ahlborn, Ulrik Lassen
Format: Article
Language:English
Published: BMC 2023-02-01
Series:BMC Cancer
Subjects:
Cancer genetics
Targeted therapies
Clinical trials
Cancer immunotherapy
Precision oncology
Tumor-agnostic therapy
Online Access:https://doi.org/10.1186/s12885-023-10632-9

Internet

https://doi.org/10.1186/s12885-023-10632-9

Similar Items